Related Experiment Video
Updated: Jul 28, 2026

The Polyvinyl Alcohol Sponge Model Implantation
Published on: April 18, 2012
Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population
James R Walker1, Jeffrey E Korte2, Aimee L McRae-Clark3
1Carolina Center for Behavioral Health, Greer, South Carolina.
Medication adherence for alcohol use disorder is low overall. Disulfiram showed significantly lower adherence compared to oral and injectable naltrexone in a Veterans Affairs study.
Area of Science:
- Pharmacology
- Public Health
- Clinical Medicine
Background:
- Medications approved by the U.S. Food and Drug Administration (FDA) are available for treating alcohol use disorders (AUDs).
- Medication effectiveness is contingent upon patient adherence to prescribed treatment regimens.
- Understanding adherence differences across AUD medications is crucial for optimizing clinical outcomes and treatment selection.
Purpose of the Study:
- To identify and compare adherence rates among FDA-approved medications for alcohol use disorder.
- To determine if significant differences in medication adherence exist between commonly prescribed AUD treatments.
Main Methods:
- A retrospective chart review of Veterans Affairs (VA) patients in the VISN-7 region (South Carolina and Georgia) from 2010-2015.
- Adherence was calculated as the percentage of days medication was available over a 6-month period based on prescription fills.
- Statistical analyses included chi-square, t tests, and logistic/linear regression to compare adherence across disulfiram, acamprosate, oral naltrexone, and extended-release injectable naltrexone.
Main Results:
- Mean medication availability (adherence) was 41.3% for disulfiram, 44.7% for acamprosate, 49.8% for oral naltrexone, and 54.6% for extended-release injectable naltrexone.
- Significant differences in adherence were observed between disulfiram and oral naltrexone (p = .002), and disulfiram and extended-release injectable naltrexone (p = .004).
- Achieving 80% adherence was substantially lower for disulfiram (11.9%) compared to oral naltrexone (22.7%) and extended-release injectable naltrexone (24.4%).
Conclusions:
- Overall adherence to medication-assisted treatment for alcohol use disorder remains low across all evaluated FDA-approved medications.
- Disulfiram demonstrated significantly lower adherence rates compared to both oral naltrexone and extended-release injectable naltrexone.
- These findings highlight potential disparities in adherence that may influence treatment effectiveness for AUDs.
More Related Videos
08:20Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure
Published on: January 18, 2021
08:37Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
Published on: November 15, 2024
Related Concept Videos
Drug Dependence
Drug Abuse and Addiction: Pharmacological Phenomena
CNS Depressants: Alcohol and Nicotine
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Therapeutic Drug Monitoring: Overview and Classification
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...